Get the Stockscreener App
40.38
1.10%
0.44
Celldex Therapeutics Inc stock is traded at $40.38, with a volume of 837.68K.
It is up +1.10% in the last 24 hours and up +13.24% over the past month.
Celldex Therapeutics Inc is a biopharmaceutical firm focused on mast cell biology and the development of therapeutic antibodies. Its pipeline includes monoclonal and bispecific antibodies aimed at treating severe inflammatory, allergic, autoimmune, and other mast cell-mediated diseases. The company operates in a single operating and reportable segment in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
See More
Previous Close:
$39.94
Open:
$40.38
24h Volume:
837.68K
Relative Volume:
0.82
Market Cap:
$3.17B
Revenue:
$866.00K
Net Income/Loss:
$-283.65M
P/E Ratio:
-9.4633
EPS:
-4.267
Net Cash Flow:
$-226.25M
1W Performance:
-3.74%
1M Performance:
+13.24%
6M Performance:
+75.41%
1Y Performance:
+83.38%
1-Day Range:
$40.12
$41.24
1-Week Range:
$39.45
$43.20
52-Week Range:
$21.34
$45.14
Celldex Therapeutics Inc Stock (CLDX) Company Profile
Name
Celldex Therapeutics Inc
Sector
Industry
Phone
908-200-7500
Address
53 FRONTAGE ROAD, HAMPTON
Compare CLDX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDX
Celldex Therapeutics Inc
|
40.38 | 3.14B | 866.00K | -283.65M | -226.25M | -4.267 |
VRTX
Vertex Pharmaceuticals Inc
|
548.05 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
834.04 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,039.78 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.13 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
209.46 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Celldex Therapeutics Inc Stock (CLDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Upgrade | Barclays | Underweight → Overweight |
| Mar-23-26 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Oct-21-25 | Initiated | Mizuho | Outperform |
| Oct-13-25 | Initiated | Barclays | Underweight |
| Apr-28-25 | Initiated | Canaccord Genuity | Buy |
| Mar-20-25 | Initiated | Morgan Stanley | Overweight |
| Feb-13-25 | Initiated | UBS | Buy |
| Oct-07-24 | Initiated | Citigroup | Buy |
| Sep-30-24 | Initiated | Goldman | Neutral |
| Sep-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-18-24 | Initiated | Stifel | Buy |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Dec-20-23 | Initiated | TD Cowen | Outperform |
| Nov-10-23 | Upgrade | Wells Fargo | Underweight → Equal Weight |
| Aug-22-23 | Initiated | Wells Fargo | Underweight |
| Sep-17-21 | Initiated | Jefferies | Buy |
| Sep-10-21 | Initiated | SVB Leerink | Outperform |
| Jul-22-21 | Initiated | Guggenheim | Buy |
| Feb-21-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-01-17 | Resumed | H.C. Wainwright | Buy |
| Nov-07-16 | Initiated | Aegis Capital | Buy |
| Mar-08-16 | Downgrade | Jefferies | Buy → Hold |
| Mar-07-16 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-07-16 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Mar-07-16 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-01-16 | Initiated | H.C. Wainwright | Buy |
| Aug-11-15 | Reiterated | Brean Capital | Buy |
| Aug-11-15 | Reiterated | Oppenheimer | Outperform |
| Aug-11-15 | Reiterated | ROTH Capital | Buy |
| Jun-02-15 | Reiterated | WBB Securities | Strong Buy |
| Nov-17-14 | Reiterated | ROTH Capital | Buy |
| Mar-04-14 | Reiterated | Oppenheimer | Outperform |
| Jul-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-08-13 | Reiterated | Cantor Fitzgerald | Buy |
| Feb-26-13 | Reiterated | Oppenheimer | Outperform |
| Jan-10-13 | Reiterated | Cantor Fitzgerald | Buy |
| Oct-02-12 | Reiterated | Oppenheimer | Outperform |
| Sep-14-12 | Reiterated | Cantor Fitzgerald | Buy |
View All
Celldex Therapeutics Inc Stock (CLDX) Latest News
Celldex Therapeutics, Inc. Revenue Breakdown – NASDAQ:CLDX - TradingView
Celldex (CLDX) Quarterly Results: Profit Per Share Clears Its Benchmark on the Day; Market Reaction - vinanet.vn
Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Celldex (CLDX) Momentum: Adds 0.32% to Close at $41.92 in the Current Update; Range Check - vinanet.vn
Celldex Therapeutics, Inc. $CLDX Shares Acquired by Bank of America Corp DE - MarketBeat
Celldex Therapeutics (CLDX) Slips 1.55% to $41.95 as Clinical-Stage Biotech ConsolidatesMomentum Surge Alerts - vinanet.vn
Kynam Capital (CLDX) group discloses 6.78% Celldex Therapeutics ownership stake - Stock Titan
T. Rowe Price Associates (CLDX) discloses 6.0% Celldex Therapeutics ownership on Schedule 13G - Stock Titan
Sei Investments Co. Purchases Shares of 38,152 Celldex Therapeutics, Inc. $CLDX - MarketBeat
Why Celldex Therapeutics (CLDX) Is Up 10.7% After Wider Losses And Barzolvolimab Phase 3 Progress - Sahm
HC Wainwright Issues Optimistic Forecast for CLDX Earnings - MarketBeat
Quantinno Capital Management LP Buys 42,158 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Reaches New 1-Year HighTime to Buy? - MarketBeat
Assenagon Asset Management S.A. Buys 642,171 Shares of Celldex Therapeutics, Inc. $CLDX - MarketBeat
Is Celldex Therapeutics’ (CLDX) Growing Losses With Minimal Revenue a Strategic Bet or Structural Concern? - Yahoo Finance
Celldex Therapeutics (CLDX) Could Be 130% Undervalued After Second Quarter Results - Yahoo Finance
Celldex Therapeutics (CLDX) Stock Trades At A Premium Despite A 102% Return - Yahoo Finance
What Is Celldex Therapeutics (CLDX) Signaling With Its Mixed Pipeline Update? - Yahoo Finance
First Trust Advisors LP Has $2.17 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - MarketBeat
Celldex Therapeutics (NASDAQ:CLDX) Issues Earnings Results, Beats Estimates By $0.12 EPS - MarketBeat
Morgan Stanley Boosts Celldex Therapeutics (NASDAQ:CLDX) Price Target to $46.00 - MarketBeat
Celldex Therapeutics Inc (CLDX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Celldex Therapeutics, Inc. Stock 12‑Month Price Target Raised to $58.07, Implies 40% Upside - TradingView
Barclays Forecasts Strong Price Appreciation for Celldex Therapeutics (NASDAQ:CLDX) Stock - MarketBeat
CLDX SWOT Analysis: Financial Challenges and Opportunities Revea - GuruFocus
Celldex Reports Second Quarter Financial Results and Provides Corporate Update - The Manila Times
Celldex Therapeutics earnings beat by $0.12, revenue fell short of estimates - Investing.com Canada
Celldex Q2 FY26 net loss widens to $73.5 million; R&D expenses climb to $67.5 million - Bitget
Celldex Therapeutics (CLDX) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Celldex: Q2 Earnings Snapshot - Barchart.com
Celldex Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q2 Revenue $0.0M - marketscreener.com
Celldex Therapeutics, Inc. 2026: Revenue $22K, EPS ($0.94) — 10-Q Summary - TradingView
Celldex Therapeutics (NASDAQ: CLDX) ramps barzolvolimab spend, raises $324M - Stock Titan
Celldex Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Celldex reports Q2 net loss of $73.5M; cash and marketable securities $717.6M at June 30, 2026 - TradingView
Celldex Therapeutics (NASDAQ:CLDX) Sets New 52-Week HighTime to Buy? - MarketBeat
Celldex Therapeutics stock hits 52-week high at $40.30 By Investing.com - Investing.com South Africa
Celldex Therapeutics stock hits 52-week high at $40.30 - Investing.com
Celldex Therapeutics earnings up next as Phase III data looms - Investing.com
Chronic Urticaria Clinical Trial Landscape Becomes Increasingly Crowded with 20+ Pharma Companies | DelveInsight - The Manila Times
CLDX Q2'26 Earnings: EPS estimate is (1.06) USD - TradingView
Dimensional Fund Advisors LP Has $33.60 Million Stock Holdings in Celldex Therapeutics, Inc. $CLDX - marketbeat.com
Celldex Therapeutics, Inc. (CLDX) Stock Analysis: Biotechnology Innovator with 51% Potential Upside - DirectorsTalk Interviews
Celldex Therapeutics, Inc. $CLDX Shares Sold by Segall Bryant & Hamill LLC - MarketBeat
Celldex Therapeutics (CLDX) Eases 1.1% as Shares Test Middle of Trading RangeTriple EMA - vinanet.vn
CLDX Q2'26 Earnings: revenue estimate is 734.92K USD - TradingView
Wells Fargo & Company Issues Positive Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - MarketBeat
Eversept Partners LP Has $56.72 Million Stock Position in Celldex Therapeutics, Inc. $CLDX - MarketBeat
CLDX|Celldex Therapeutics Inc|Price:35.660|Chg%:+0.380 - TradingKey
Celldex Therapeutics Inc (CLDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Celldex Therapeutics Inc Stock (CLDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.21%
1.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):